Trials / Unknown
UnknownNCT02041260
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Thomas Jefferson University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II, non-randomized, open-label study to determine the efficacy of cabozantinib as a firstline treatment for patients with differentiated thyroid cancer (DTC). Subjects will receive drug at a starting dose of 60mg PO QD. Subjects can receive drug as long as they continue to derive clinical benefit or until they experience unacceptable drug-related toxicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2022-05-01
- Completion
- 2022-05-01
- First posted
- 2014-01-22
- Last updated
- 2021-10-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02041260. Inclusion in this directory is not an endorsement.